uniQure (QURE) Cash from Investing Activities (2016 - 2026)
uniQure (QURE) posted quarterly Cash from Investing Activities of $53.3 million for Q2 2026, down 27.12% year-over-year from $73.1 million in Q2 2025, and down 45.96% quarter-over-quarter from $98.6 million in Q1 2026.
Analysis
uniQure (QURE) Cash from Investing Activities (2016 - 2026) Analysis & Trends
uniQure's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $53.3 million for Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 27.12% year-over-year to $53.3 million; the TTM figure through Jun 2026 stood at -$263.0 million (down 330.24% YoY), while the FY2025 annual figure was -$321.6 million, down 297.35% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at $53.3 million, down from $98.6 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $98.6 million in Q1 2026, with the low at -$441.4 million in Q4 2025.
- The 5-year median for Cash from Investing Activities is $23.3 million (2025), against an average of -$22.0 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 6103.16% in 2023, then surged 2041.4% in 2024.
- uniQure's Cash from Investing Activities stood at -$168.2 million in 2022, then surged by 135.41% to $59.6 million in 2023, then tumbled by 144.7% to -$26.6 million in 2024, then sank by 1557.79% to -$441.4 million in 2025, then soared by 112.07% to $53.3 million in 2026.
- Business Quant data shows QURE's Cash from Investing Activities at $53.3 million in Q2 2026, $98.6 million in Q1 2026, and -$441.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 53.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 53.26 Mn |
| Mar 31, 2026 | 98.56 Mn |
| Dec 31, 2025 | -441.37 Mn |
| Sep 30, 2025 | 26.58 Mn |
| Jun 30, 2025 | 73.07 Mn |
| Mar 31, 2025 | 20.10 Mn |
| Dec 31, 2024 | -26.62 Mn |
| Sep 30, 2024 | 47.67 Mn |
| Jun 30, 2024 | 77.94 Mn |
| Mar 31, 2024 | 63.99 Mn |
| Dec 31, 2023 | 59.56 Mn |
| Sep 30, 2023 | -314.07 Mn |
| Jun 30, 2023 | 45.83 Mn |
| Mar 31, 2023 | 2.99 Mn |
| Dec 31, 2022 | -168.21 Mn |
| Sep 30, 2022 | -5.06 Mn |
| Jun 30, 2022 | -4.58 Mn |
| Mar 31, 2022 | -4.88 Mn |
| Dec 31, 2021 | -3.55 Mn |
| Sep 30, 2021 | -57.64 Mn |